Esophageal and Gastroesophageal Junction Carcinoma

Esophageal and Gastroesophageal Junction Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,309 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 460
Recruiting: 254
Ph III recruiting: 40
Growth YoY: +36.1%
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 29.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (120)

clinicaltrialsPublishedShowing 1–19 of 19 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05312372	S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC	withdrawn	Phase 1 / Phase 2	0	Institut de Recherches Internationales ServierOTHER	0	Feb 17, 2026	clinicaltrials
NCT07283848	Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma	withdrawn	Phase 2	0	Massachusetts General HospitalOTHER	1	Dec 26, 2025	clinicaltrials